{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Accounting and Accountants", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Philidor Rx Services LLC", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Bausch & Lomb Incorporated", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "6", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "7", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/29/business/dealbook/valeants-accounting-error-a-warning-sign-of-bigger-problems.html", "document_type": "article", "byline": {"person": [{"lastname": "EAVIS", "firstname": "Peter", "role": "reported", "organization": "", "rank": 1}], "original": "By PETER EAVIS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbWide.jpg", "legacy": {"wide": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/29/business/29db-valeantaccounting/29db-valeantaccounting-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1208", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Investors have other reasons to remain concerned about the accuracy of the company\u2019s financial statements.", "pub_date": "2016-03-29T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Valeant\u2019s Small Accounting Error Is a Warning Sign to Investors of Bigger Problems", "main": "Valeant\u2019s Accounting Error a Warning Sign of Bigger Problems"}, "print_page": "3", "snippet": "Investors have other reasons to remain concerned about the accuracy of the company\u2019s financial statements.", "_id": "56f99b2238f0d874a87cb052", "slideshow_credits": null, "abstract": "Admission by Valeant Pharmaceuticals that it improperly booked $58 million in revenue, while minor in comparison to company's overall financial scope, could lend credence to longstanding accusations of flawed accounting practices; company has acknowledged that other lapses may require review. "}